SLAMF8, a potential new immune checkpoint molecule, is associated with the prognosis of colorectal cancer

Sung, 2021, global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA: Cancer J. Clin., 71, 209 Siegel, 2021, Cancer statistics, 2021, CA: Cancer J. Clin., 71, 7 Morgan, 2023, Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN, Gut, 72, 338, 10.1136/gutjnl-2022-327736 Jung, 2021, Prediction of cancer incidence and mortality in Korea, Cancer Res. Treat., 53, 316, 10.4143/crt.2021.290 Biller, 2021, Diagnosis and treatment of metastatic colorectal cancer: a review, JAMA, 325, 669, 10.1001/jama.2021.0106 Khan, 2020, Soluble PD-1: predictive, prognostic, and therapeutic value for cancer immunotherapy, Front. Immunol., 11, 10.3389/fimmu.2020.587460 Ganesh, 2019, Immunotherapy in colorectal cancer: rationale, challenges and potential, Nat. Rev. Gastroenterol. Hepatol., 16, 361, 10.1038/s41575-019-0126-x Fan, 2021, Immunotherapy in colorectal cancer: current achievements and future perspective, Int. J. Biol. Sci., 17, 3837, 10.7150/ijbs.64077 Haspot, 2008, Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway, Blood, 112, 2149, 10.1182/blood-2007-12-127449 Friedman, 2016, Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review, JAMA Oncol., 2, 1346, 10.1001/jamaoncol.2016.1051 Sugimoto, 2020, SLAM family member 8 is expressed in and enhances the growth of anaplastic large cell lymphoma, Sci. Rep., 10, 2505, 10.1038/s41598-020-59530-1 Zhang, 2021, SLAMF8 expression predicts the efficacy of anti-PD1 immunotherapy in gastrointestinal cancers, Clin. Transl. Immunol., 10, e1347, 10.1002/cti2.1347 Angulo, 2019, Viral CD229 (Ly9) homologs as new manipulators of host immunity, J. Leukoc. Biol., 105, 947, 10.1002/JLB.2MR1018-413R Wu, 2016, SLAM family receptors in normal immunity and immune pathologies, Curr. Opin. Immunol., 38, 45, 10.1016/j.coi.2015.11.003 O'Connell, 2021, SLAMF7 signaling reprograms T cells toward exhaustion in the tumor microenvironment, J. Immunol., 206, 193, 10.4049/jimmunol.2000300 Simmons, 2022, SLAMF7 engagement superactivates macrophages in acute and chronic inflammation, Sci. Immunol., 7, eabf2846, 10.1126/sciimmunol.abf2846 Loyal, 2020, SLAMF7 and IL-6R define distinct cytotoxic versus helper memory CD8(+) T cells, Nat. Commun., 11, 6357, 10.1038/s41467-020-19002-6 Calpe, 2008, The SLAM and SAP gene families control innate and adaptive immune responses, Adv. Immunol., 97, 177, 10.1016/S0065-2776(08)00004-7 Agresta, 2020, CD244 represents a new therapeutic target in head and neck squamous cell carcinoma, J. Immunother. Cancer, 8, 10.1136/jitc-2019-000245 Zou, 2019, Costimulatory checkpoint SLAMF8 is an independent prognosis factor in glioma, CNS Neurosci. Ther., 25, 333, 10.1111/cns.13041 Havel, 2019, The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy, Nat. Rev. Cancer, 19, 133, 10.1038/s41568-019-0116-x Lichtenstern, 2020, Immunotherapy, inflammation and colorectal cancer, Cells, 9, 10.3390/cells9030618 Kishore, 2021, Current advancements and future perspectives of immunotherapy in colorectal cancer research, Eur. J. Pharmacol., 893, 10.1016/j.ejphar.2020.173819 Lin, 2020, Crosstalk between the MSI status and tumor microenvironment in colorectal cancer, Front. Immunol., 11, 2039, 10.3389/fimmu.2020.02039 Zhang, 2022, Neoadjuvant immunotherapy for MSI-H/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities, Front. Immunol., 13 Lizardo, 2020, Immunotherapy efficacy on mismatch repair-deficient colorectal cancer: from bench to bedside, Biochim. Biophys. Acta Rev. Cancer, 1874, 10.1016/j.bbcan.2020.188447 Franke, 2019, Immunotherapy for colorectal cancer: a review of current and novel therapeutic approaches, J. Natl. Cancer Inst., 111, 1131, 10.1093/jnci/djz093 Gelsomino, 2016, The evolving role of microsatellite instability in colorectal cancer: a review, Cancer Treat. Rev., 51, 19, 10.1016/j.ctrv.2016.10.005 Wolf, 2020, TIM3 comes of age as an inhibitory receptor, Nat. Rev. Immunol., 20, 173, 10.1038/s41577-019-0224-6 Kandel, 2021, The TIM3/Gal9 signaling pathway: an emerging target for cancer immunotherapy, Cancer Lett., 510, 67, 10.1016/j.canlet.2021.04.011 Solinas, 2019, Significance of TIM3 expression in cancer: from biology to the clinic, Semin. Oncol., 46, 372, 10.1053/j.seminoncol.2019.08.005 Herrera-Camacho, 2019, Cancer immunotherapy using anti-TIM3/PD-1 bispecific antibody: a patent evaluation of EP3356411A1, Expert Opin. Ther. Pat., 29, 587, 10.1080/13543776.2019.1637422 Chen, 2022, TIM3(+) cells in gastric cancer: clinical correlates and association with immune context, Br. J. Cancer, 126, 100, 10.1038/s41416-021-01607-3 Zhao, 2021, TIM-3: an update on immunotherapy, Int. Immunopharmacol., 99, 10.1016/j.intimp.2021.107933 Huang, 2020, VISTA: an immune regulatory protein checking tumor and immune cells in cancer immunotherapy, J. Hematol. Oncol., 13, 83, 10.1186/s13045-020-00917-y Maruhashi, 2020, LAG-3: from molecular functions to clinical applications, J. Immunother. Cancer, 8, 10.1136/jitc-2020-001014 Chauvin, 2020, TIGIT in cancer immunotherapy, J. Immunother. Cancer, 8, 10.1136/jitc-2020-000957 Sharma, 2021, LILRB4 suppresses immunity in solid tumors and is a potential target for immunotherapy, J. Exp. Med., 218, 10.1084/jem.20201811 García, 2007, SLAM and CD31: signaling molecules involved in cytokine secretion during the development of innate and adaptive immune responses, Cytokine Growth Factor Rev., 18, 85, 10.1016/j.cytogfr.2007.01.008 Lewinsky, 2018, CD84 regulates PD-1/PD-L1 expression and function in chronic lymphocytic leukemia, J Clin Invest, 128, 5465, 10.1172/JCI96610 van de Donk, 2021, CAR T-cell therapy for multiple myeloma: state of the art and prospects, Lancet Haematol., 10.1016/S2352-3026(21)00057-0 Zeng, 2020, Combined deficiency of SLAMF8 and SLAMF9 prevents endotoxin-induced liver inflammation by downregulating TLR4 expression on macrophages, Cell Mol. Immunol., 17, 153, 10.1038/s41423-018-0191-z Teng, 2022, SLAMF8 participates in acute renal transplant rejection via TLR4 pathway on pro-inflammatory macrophages, Front. Immunol., 13, 10.3389/fimmu.2022.846695 Vitale, 2019, Macrophages and metabolism in the tumor microenvironment, Cell Metab., 30, 36, 10.1016/j.cmet.2019.06.001 Petty, 2017, Tumor-associated macrophages: implications in cancer immunotherapy, Immunotherapy, 9, 289, 10.2217/imt-2016-0135 DeNardo, 2019, Macrophages as regulators of tumour immunity and immunotherapy, Nat. Rev. Immunol., 19, 369, 10.1038/s41577-019-0127-6 Pan, 2020, Tumor-associated macrophages in tumor immunity, Front. Immunol., 11, 10.3389/fimmu.2020.583084